Home › Funds › ROYAL LONDON ASSET MANAGEMENT LTD › RPRX
ROYAL LONDON ASSET MANAGEMENT LTD position in RPRX
ROYALTY PHARMA PLC · Health Care
ROYAL LONDON ASSET MANAGEMENT LTD reported holding 5,973,705 shares of RPRX (ROYALTY PHARMA PLC) in its Q3 2026 13F filing — a position valued at US$348.6M, representing 0.64% of its reported portfolio and ranking #22 among its reported holdings. ROYAL LONDON ASSET MANAGEMENT LTD has disclosed RPRX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How ROYAL LONDON ASSET MANAGEMENT LTD's RPRX position evolved
ROYAL LONDON ASSET MANAGEMENT LTD first disclosed a stake in RPRX in Q3 2023 at 318,514 shares (US$8.6M). The position peaked in Q3 2026 at 5,973,705 shares, worth US$348.6M. Across 13 filings, ROYAL LONDON ASSET MANAGEMENT LTD increased the stake 9 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 5,973,705 shares valued at US$348.6M — an increase of 1,654,110 shares quarter over quarter.. Notable position changes include a 54% trim in Q2 2024 (shares rose 7% over the following quarter), a 2019% increase in Q1 2026 (shares rose 17% over the following quarter), a 38% increase in Q3 2026 (shares rose 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 318.51K | $8.65M | New |
| Q4 2023 | 321.80K | $9.04M | Add |
| Q1 2024 | 339.56K | $10.31M | Add |
| Q2 2024 | 155.88K | $4.11M | Reduce |
| Q3 2024 | 160.18K | $4.53M | Add |
| Q4 2024 | 177.69K | $4.53M | Add |
| Q1 2025 | 181.54K | $5.65M | Add |
| Q2 2025 | 178.47K | $6.43M | Reduce |
| Q3 2025 | 178.47K | $6.30M | Hold |
| Q4 2025 | 179.68K | $6.94M | Add |
| Q1 2026 | 3.81M | $182.69M | Add |
| Q2 2026 | 4.32M | $242.20M | Add |
| Q3 2026 | 5.97M | $348.63M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RPRX and 13F data
RPRX (ROYALTY PHARMA PLC) is a Health Care company. 47 other funds we track also report a position in RPRX — the largest reported positions include Swedbank AB (US$598.8M), Baillie Gifford & Co (US$534.1M), Caledonia (Private) Investments Pty Ltd (US$323.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RPRX
- Swedbank AB 10.26M sh · $598.81M · Q3 2026
- Baillie Gifford & Co 9.15M sh · $534.11M · Q3 2026
- Caledonia (Private) Investments Pty Ltd 5.78M sh · $323.85M · Q2 2026
- Patient Capital Management, LLC 3.42M sh · $199.71M · Q3 2026
- Dorsey Asset Management, LLC 2.46M sh · $137.74M · Q2 2026
- Regal Partners Ltd 2.45M sh · $137.25M · Q2 2026
- HOMESTEAD ADVISERS CORP 1.66M sh · $96.68M · Q3 2026
- Clark Capital Management Group, Inc. 1.66M sh · $93.24M · Q2 2026
- NEW SOUTH CAPITAL MANAGEMENT INC 1.45M sh · $84.36M · Q3 2026
More on ROYAL LONDON ASSET MANAGEMENT LTD
FAQ
How long has ROYAL LONDON ASSET MANAGEMENT LTD held RPRX?
ROYAL LONDON ASSET MANAGEMENT LTD has disclosed RPRX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is ROYAL LONDON ASSET MANAGEMENT LTD's current position in RPRX?
As of Q3 2026, ROYAL LONDON ASSET MANAGEMENT LTD holds 5.97M shares of RPRX (ROYALTY PHARMA PLC), valued at $348.63M, representing 0.64% of its reported portfolio and ranking #22.
Has ROYAL LONDON ASSET MANAGEMENT LTD been buying or selling RPRX?
In the latest 13F filing (Q3 2026), ROYAL LONDON ASSET MANAGEMENT LTD increased its position in RPRX. The position peaked in Q3 2026 at 5.97M shares.
Which other funds hold RPRX?
Other major institutional holders of RPRX include Swedbank AB, Baillie Gifford & Co, Caledonia (Private) Investments Pty Ltd, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.